profit from every $100 of sales.
$0$100
OS Therapies
$0.75-14.00% today
-60.9% in 1 year
1-year low $0.751-year high $2.24
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What OS Therapies sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$28.8 million of profit last year.
SalesProfit
OS Therapies vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| OS Therapies | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads OS Therapies's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -4 | -4 | -7 | -29 | |
| -4 | -4 | -7 | -28 | |
| -6 | -8 | -9 | -29 | |
| -0.32 | -0.38 | -1.28 | -0.98 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1 | 1 | 6 | 7 |
| Cash | 0 | 0 | 6 | 0 |
| Total debt | 10 | 15 | – | – |
| Total liabilities | 18 | 25 | 9 | 13 |
| -18 | -24 | -3 | -6 | |
| 20 | 21 | 7 | 29 | |
| – | – | – | – | |
| 35.6% | 32.4% | 271.9% | 471.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -4 | -3 | -7 | -14 | |
| – | – | – | 0 | |
| -4 | -3 | -7 | -15 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| – | 0 | 0 | 5 |
Valuation
- –
- –
- –
- 0.1×
- –
- –
- –
- -40,555.8%
- -81.9%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- 110.4%
- -56.8%
- -3,874.0%
- -163.3%
- 96.4%
- –
Growth
- –
- –
- −195,423.2%
- –
- +6.1%
Financial health
- -0.0×
- 1.25
- 21.0%
- 135.3×
- 0.05
- 0.05
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 1%of 952
Bottom 20%of 883
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 18, 2026 | -0.27 | -0.17 | −58.8% |
| Mar 31, 2026 | -0.35 | -0.14 | −157.4% |
| Nov 14, 2025 | -0.21 | -0.16 | −31.2% |
| Aug 19, 2025 | -0.19 | -0.15 | −26.7% |
| May 15, 2025 | -0.18 | -0.11 | −63.6% |
| Mar 31, 2025 | -0.24 | -0.14 | −71.4% |
| Nov 15, 2024 | -0.18 | -0.12 | −50.0% |
| Aug 14, 2024 | -0.26 | -0.26 | +0.0% |
News
A failed trial for a heart drug casts shadow over rivals developing similar therapiesMarketWatch · Nov 9, 2026BioRestorative Therapies announces 1-for-20 reverse stock splitSeeking Alpha · Sep 2, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
26No pass
Benjamin Graham
47No pass
Philip Fisher
32No pass
Peter Lynch
41No pass
Joel Greenblatt
69Pass
Charlie Munger
28No pass
Terry Smith
34No pass
Questions about OS Therapies
Is OS Therapies a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the OS Therapies AI analysis
What does OS Therapies do?
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. It is in Biotechnology.
Does OS Therapies pay a dividend?
No. OS Therapies does not pay a dividend at the moment.
Is OS Therapies stock halal?
Yes. OS Therapies passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
How has OS Therapies stock done over the past year?
Down 60.9% over the past twelve months, to $0.75. It traded between $0.75 and $2.24 and is 66.5% below its high.
Who are OS Therapies's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with OS Therapies's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.